ライフサイエンスコーパス: rheumatic

1 on between periodontal infection markers and rheumatic activity.

2 EGylated TRAIL (TRAILPEG) is profoundly anti-rheumatic against two complementary experimental RA mous

3 ), which is a gold-containing classical anti-rheumatic agent and a PKCiota-specific inhibitor, result

4 anofin, a drug initially approved as an anti-rheumatic agent, which also possesses potent antibacteri

5 Several diseases, including inflammatory rheumatic and autoimmune diseases, infections, and malig

6 igen (HLA) genes known to be associated with rheumatic and infectious diseases and complement C4 gene

7 in the 1950s revolutionized the treatment of rheumatic and inflammatory disease.

8 l strategies for arterial revascularization, rheumatic and other valvular heart disease, and symptoma

9 y with the risk of subsequent development of rheumatic autoimmune diseases in women, including rheuma

10 stemic lupus erythematosus, thyroiditis, and rheumatic autoimmune diseases.

11 ed attention on the role of B lymphocytes in rheumatic autoimmune/inflammatory diseases (RAIDs), but

12 ole in the etiology of both degenerative and rheumatic cardiac valve diseases.

13 responses to cardiac myosin were similar in rheumatic carditis among a small sample of worldwide pop

14 An analysis of rheumatic carditis in a Pacific Islander family confirme

15 f human cardiac myosin in the development of rheumatic carditis in humans.

16 ort suggests that cardiac myosin epitopes in rheumatic carditis target the S2 region of cardiac myosi

17 yosin and are similar among populations with rheumatic carditis worldwide, regardless of the infectin

18 ocarditis; however, in the developing world, rheumatic carditis, Trypanosoma cruzi, and bacterial inf

19 A tool called the Work Experience Survey-Rheumatic Conditions (WES-RC), which identifies barriers

20 d as a central pathogenic factor in multiple rheumatic conditions and has been shown to act via a wid

21 s losses associated with arthritis and other rheumatic conditions and the increment in such costs att

22 Arthritis and other rheumatic conditions continue to be a large and growing

23 ch costs attributable to arthritis and other rheumatic conditions in the US in 2003, and to compare t

24 Estimates for many specific rheumatic conditions rely on a few, small studies of unc

25 re we discuss the complications of childhood rheumatic conditions that necessitate critical intervent

26 nditures attributable to arthritis and other rheumatic conditions was $1,752 ($1,762 in 1997), for a

27 uboptimal healthcare quality for four common rheumatic conditions, a finding that parallels trends in

28 mining quality of care for several prevalent rheumatic conditions, including rheumatoid arthritis, os

29 on samples are unavailable for most specific rheumatic conditions, we derived estimates from publishe

30 ive data on work barriers from patients with rheumatic conditions.

31 s in healthcare quality for populations with rheumatic conditions.

32 Rheumatic diagnoses, age at diagnosis, sex, and early us

33 Causes of death were related to the rheumatic diagnosis (including complications) in 39 pati

34 ic bacteriuria (AB) in women with autoimmune rheumatic disease (ARD) are scarce.

35 lales abundance are implicated in arthritis, rheumatic disease and diabetes.

36 acity and physical activity in children with rheumatic disease and examines the role of exercise in m

37 However, patients with active underlying rheumatic disease and secondary infection who are being

38 t drugs used in other specialties may induce rheumatic disease and vigilance on making a diagnosis is

39 Scleroderma is a chronic autoimmune rheumatic disease associated with widespread tissue fibr

40 ologists document and improve the quality of rheumatic disease care.

41 siological mechanisms of musculoskeletal and rheumatic disease caused by SINV are inadequately unders

42 c lupus erythematosus (SLE), an inflammatory rheumatic disease characterized by autoantibody producti

43 limitations in children and adolescents with rheumatic disease despite advances in the pharmacologica

44 ured medical record abstraction, we examined rheumatic disease diagnosis, cumulative steroid use, dur

45 men will develop an inflammatory autoimmune rheumatic disease during their lifetime.

46 S: New genetic associations in patients with rheumatic disease have been reported for disease modifyi

47 literature related to the risk of autoimmune rheumatic disease in association with pregnancy history.

48 Although mortality from rheumatic disease in children is rare, the most severe d

49 squito-borne Alphavirus, causes debilitating rheumatic disease in humans that can last for weeks to m

50 Gout is a common rheumatic disease in humans which is characterized by el

51 caring for patients, few reports within the rheumatic disease literature have focused on ethical iss

52 nile idiopathic arthritis (JIA) is a chronic rheumatic disease of childhood.

53 e risk of developing inflammatory autoimmune rheumatic disease over a lifetime.

54 omplaints, which can present as a definitive rheumatic disease such as calcium pyrophosphate dihydrat

55 Patients with the autoimmune rheumatic disease systemic lupus erythematosus (SLE) hav

56 irus (CHIKV) infection causes a debilitating rheumatic disease that can persist for months to years,

57 eins, which are autoantigens associated with rheumatic disease that function in RNA biogenesis and qu

58 so called scleroderma, is an immune-mediated rheumatic disease that is characterised by fibrosis of t

59 all lifetime risk of inflammatory autoimmune rheumatic disease was 8.4% for women and 5.1% for men.

60 e second most common inflammatory autoimmune rheumatic disease was PMR, with a lifetime risk of 2.4%

61 in unaffected cases, independent of maternal rheumatic disease, season at highest risk of cardiac NL

62 mediated diseases (diabetes mellitus type 1, rheumatic disease, thyroid disease, vitiligo, alopecia a

63 Macrophage activation syndrome is the rheumatic disease-associated member of a group of hyperi

64 e adverse metabolic features associated with rheumatic disease.

65 se phenotype in a mouse model of RRV-induced rheumatic disease.

66 pediatric MAS varies based on the underlying rheumatic disease.

67 e in both adults and children diagnosed with rheumatic disease.

68 estimated the sex-specific lifetime risk of rheumatic disease.

69 MTX initiation among diabetes patients with rheumatic disease.

70 obin (HbA(1c) ) in diabetes patients without rheumatic disease.

71 rtunities to better understand the causes of rheumatic disease.

72 increasingly recognized in association with rheumatic disease.

73 recent advances in the field of diabetes and rheumatic disease.

74 Sjogren's syndrome is a common autoimmune rheumatic disease.

75 ity of life in children and adolescents with rheumatic disease.

76 ed with adverse birth outcomes in women with rheumatic disease.

77 5.5% vs. 0.1%), pancreatic (1.7% vs. 0%) and rheumatic diseases (7.2% vs. 1.2%; all P < 0.01).

78 ith PBC (n = 30), other autoimmune liver and rheumatic diseases (n = 20), and healthy individuals (n

79 btained from our population-based studies of rheumatic diseases among residents of Olmsted County, Mi

80 ecificity in relation to patients with other rheumatic diseases and healthy controls was >90%.

81 SLE patients compared to patients with other rheumatic diseases and healthy subjects.

82 ic abnormality distinguishes SJIA from other rheumatic diseases and is caused by both genetic and acq

83 Patients with inflammatory rheumatic diseases and periodontitis share common pathog

84 th content that was relevant to rheumatology/rheumatic diseases and that primarily focused on ethics.

85 isks of malignancy associated with pediatric rheumatic diseases and their treatments are needed.

86 Features that can have similarities to many rheumatic diseases are being increasingly reported.

87 Autoantibodies in the systemic rheumatic diseases are clinically useful biomarkers of t

88 As most of the rheumatic diseases are multisystem, it is worthwhile exa

89 ystem dysfunction is common in children with rheumatic diseases complicated by MAS, and more organ sy

90 underlying the pathogenenesis of autoimmune rheumatic diseases has led to targeted biological treatm

91 The options for treating rheumatic diseases have improved, but many patients are

92 ging typical for the most commonly diagnosed rheumatic diseases in children, such as juvenile idiopat

93 Differential diagnosis of rheumatic diseases is performed on the basis of localiza

94 basis of the disease has lagged behind other rheumatic diseases mainly because of the difficulty in d

95 e diagnostics and treatment of patients with rheumatic diseases of the musculoskeletal system, includ

96 Patients with rheumatic diseases receiving certain therapeutic agents

97 isks for rheumatoid arthritis (RA) and other rheumatic diseases remains poor, despite advances in kno

98 nsive cells in both the bona fide autoimmune rheumatic diseases rheumatoid arthritis and systemic lup

99 afety in rheumatoid arthritis (RA) and other rheumatic diseases such as juvenile idiopathic arthritis

100 of sarcoidosis coexisting with or mimicking rheumatic diseases such as systemic lupus erythematosus,

101 A and TST in a large cohort of patients with rheumatic diseases suggest that the IGRA provides greate

102 The spondyloarthropathies are a group of rheumatic diseases that are associated with inflammation

103 ppressive agents often require patients with rheumatic diseases to be monitored or managed in the ped

104 hat the overall mortality rate for pediatric rheumatic diseases was not increased.

105 t four groups of drugs to potentially induce rheumatic diseases were anti-tumour necrosis factor (TNF

106 ystemic lupus erythematosus (SLE), and other rheumatic diseases were identified by diagnostic codes f

107 in the treatment of patients with autoimmune rheumatic diseases who have failed conventional therapy.

108 nt IFN pathways active in tissues of complex rheumatic diseases will be critical to classify disease,

109 Among the rheumatic diseases, 43 cases of PML (0.44%) were associa

110 d (210 SLE patients, 178 patients with other rheumatic diseases, and 205 healthy subjects).

111 nts with established RA, patients with other rheumatic diseases, and healthy adults were assayed for

112 y was confined to hospitalized patients with rheumatic diseases, and it was also limited by the lack

113 are key pathogenic derangements in systemic rheumatic diseases, and these insights are leading to ch

114 Ultrasound cannot identify specific rheumatic diseases, but it does allow for an evaluation

115 portant mediator of cartilage destruction in rheumatic diseases, but our understanding of the upstrea

116 ta concerning vaccination among persons with rheumatic diseases, focusing on the effects of immune-mo

117 Spondyloarthropathies belong to a group of rheumatic diseases, in which inflammatory changes affect

118 Finally, rheumatic diseases, including rheumatoid arthritis and s

119 RA, as well as other inflammatory autoimmune rheumatic diseases, including systemic lupus erythematos

120 trasound is used in the initial diagnosis of rheumatic diseases, monitoring of the effectiveness of t

121 inherited or acquired, children with severe rheumatic diseases, most notably systemic juvenile idiop

122 As with many rheumatic diseases, there is growing interest in using g

123 In today's modern day treatment of rheumatic diseases, ultrasonography and magnetic resonan

124 es in the biological treatment of autoimmune rheumatic diseases, with a particular focus on systemic

125 tological malignancies, Crohn's disease, and rheumatic diseases--have been associated with PML.

126 ntal role in the diagnosis and monitoring of rheumatic diseases.

127 ertinent to the pathogenesis or treatment of rheumatic diseases.

128 h are defective, but correctable, in several rheumatic diseases.

129 elopment of inflammatory diseases, including rheumatic diseases.

130 l syndromes that closely mimic other primary rheumatic diseases.

131 nized for noninfectious association with the rheumatic diseases.

132 ty for SLE and 87% specificity against other rheumatic diseases.

133 be difficult to distinguish from idiopathic rheumatic diseases.

134 , including systemic lupus erythematosus and rheumatic diseases.

135 gnify new associations between drugs and the rheumatic diseases.

136 ions of personalized, targeted therapies for rheumatic diseases.

137 ning an effective treatment strategy for the rheumatic diseases.

138 limit the safety of colchicine for treating rheumatic diseases.

139 d localized and generalized bone loss in the rheumatic diseases.

140 ide an effective nonsurgical intervention in rheumatic diseases.

141 emity joint alignment, structure and pain in rheumatic diseases.

142 f foot orthotics and footwear in adults with rheumatic diseases.

143 and interventions that lessen the impact of rheumatic diseases.

144 medical conditions, including the autoimmune rheumatic diseases.

145 of the frequency of PML among patients with rheumatic diseases.

146 for the pathogenesis of chronic inflammatory rheumatic diseases.

147 ML occurs more commonly in SLE than in other rheumatic diseases.

148 with juvenile idiopathic arthritis and other rheumatic diseases.

149 ns of anti-PAD-4 autoantibodies in different rheumatic diseases.

150 , may influence the occurrence of autoimmune rheumatic diseases.

151 its role in the pathogenesis of more common rheumatic diseases.

152 majority of inflammatory and noninflammatory rheumatic diseases.

153 se of their recent success in treating other rheumatic diseases.

154 at may be also useful in patients with other rheumatic diseases.

155 lines on the use of ultrasound modalities in rheumatic diseases.

156 or for work disability in a diverse array of rheumatic diseases.

157 udied areas include the muscles, tendons and rheumatic diseases.

158 lidates uPA as a novel therapeutic target in rheumatic diseases.

159 , chronic obstructive pulmonary disease, and rheumatic diseases.

160 pregnancy and the future risk of autoimmune rheumatic diseases.

161 are critical to the pathogenesis of systemic rheumatic diseases.

162 been tested as therapeutics for inflammatory rheumatic diseases.

163 pregnancy-related research in patients with rheumatic diseases.

164 e of this biologic is now expanding to other rheumatic diseases.

165 incompletely to the treatment of the primary rheumatic disorder and pain syndromes such as fibromyalg

166 7 of 82 (9.5%) patients with other types of rheumatic disorders and in 2 of 47 (4.2%) healthy subjec

167 disease-specific manifestations of childhood rheumatic disorders present pediatric rheumatologists an

168 nts compared with those with noninflammatory rheumatic disorders, and to examine severity and anti-tu

169 hich will increase the number of people with rheumatic disorders, growth in the Gross Domestic Produc

170 particularly related to shoes, footwear and rheumatic disorders, may be an important modifiable fact

171 either primary or in association with other rheumatic disorders, may experience benefit from new the

172 esents similarly to reactive, neoplastic, or rheumatic disorders.

173 rference with B cell counts and functions in rheumatic disorders.

174 Against Rheumatism database of patients with rheumatic disorders.

175 vity, compound T-614 (also known as the anti-rheumatic drug iguratimod), and found that, in addition

176 gender and concurrent disease modifying anti-rheumatic drug treatment were used to assess association

177 response to synthetic disease modifying anti-rheumatic drugs (DMARDs) from 35 rheumatology department

178 ression with biologic disease-modifying anti-rheumatic drugs (DMARDs), such as tumour necrosis factor

179 ipants had been using disease-modifying anti-rheumatic drugs, and 20 had also been using anti-TNF-alp

180 ed treatment with any disease-modifying anti-rheumatic drugs, were enrolled from eight secondary care

181 CR) results, face psychosocial disorders and rheumatic, ear-nose-throat, neurocognitive, and ophthalm

182 ation of illness, Disease Activity Score 28, rheumatic factor [RF], anti-cyclic citrullinated peptide

183 atient-years), 19 (0.6%) had recurrent acute rheumatic fever (3.49/1000 patient-years), and 20 (0.7%)

184 Although acute rheumatic fever (ARF) and its sequel, rheumatic heart di

185 gated adverse outcomes for people with acute rheumatic fever (ARF) and rheumatic heart disease (RHD)

186 Both rheumatic fever (cases) and tuberculosis (controls) were

187 The authors compared the prevalence of rheumatic fever among the relatives of 33 children admit

188 tives of 33 children admitted for "incident" rheumatic fever and 33 control children admitted in a tu

189 iated with serious sequelae, including acute rheumatic fever and acute glomerulonephritis.

190 he current hypotheses of the pathogenesis of rheumatic fever and group A streptococcal autoimmune seq

191 rategies for the primary prevention of acute rheumatic fever and rheumatic heart disease in children

192 Acute rheumatic fever and rheumatic heart disease remain major

193 Acute rheumatic fever and subsequent rheumatic heart disease r

194 ints and cardiac valves in disorders such as rheumatic fever and systemic lupus erythematosus remain

195 presence of an "inherited predisposition" to rheumatic fever because the disease was more prevalent a

196 tional guidelines for the diagnosis of acute rheumatic fever by defining high-risk populations, recog

197 The incidence of acute rheumatic fever declined from 6.1 to 3.7 cases/100,000 (

198 storic Jones criteria used to diagnose acute rheumatic fever in the context of the current epidemiolo

199 of population-specific differences in acute rheumatic fever presentation and changes in presentation

200 t of GAS pharyngitis are cornerstones of the Rheumatic Fever Prevention Programme, but these are hind

201 Acute rheumatic fever remains a serious healthcare concern for

202 of New Zealand where the incidence of acute rheumatic fever remains unacceptably high.

203 d aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in

204 r transient ischemic attack, recurrent acute rheumatic fever, and infective endocarditis.

205 fections, myringotomy, measles, hepatitis A, rheumatic fever, common colds, rubella and chronic sinus

206 Cardiovascular Disease in the Young and its Rheumatic Fever, Endocarditis, and Kawasaki Disease Comm

207 ation under the auspices of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Cou

208 ans to diagnose cardiac involvement in acute rheumatic fever, even when overt clinical findings are n

209 l on the hereditary versus social origins of rheumatic fever, Read, Ciocco, and Taussig, from Johns H

210 homologue in certain diseases such as acute rheumatic fever, suggest that SOK plays an important rol

211 Once primarily caused by rheumatic fever, the most common pathogenesis today is a

212 othesis is proven in a few illnesses such as rheumatic fever, there is no definitive evidence of an i

213 tries with the added factors of SH, C'D, and rheumatic fever.

214 logic manifestation of streptococcal-induced rheumatic fever.

215 ly with a decrease in the incidence of acute rheumatic fever.

216 in timely fashion in order to prevent acute rheumatic fever.

217 at which group A streptococcus causes acute rheumatic fever.

218 skin infection and pharyngitis-induced acute rheumatic fever.

219 a tuberculosis clinic for reasons other than rheumatic fever.

220 f carditis as a major manifestation of acute rheumatic fever.

221 sses and 2 (0.28%) were diagnosed with acute rheumatic fever.

222 art disease were older than children without rheumatic heart disease (median age [interquartile range

223 Rheumatic heart disease (RHD) after group A streptococcu

224 people with acute rheumatic fever (ARF) and rheumatic heart disease (RHD) and the effect of comorbid

225 Rheumatic heart disease (RHD) is a leading cause of prem

226 Echocardiographic screening for rheumatic heart disease (RHD) is becoming more widesprea

227 Rheumatic heart disease (RHD) remains a major public hea

228 High-risk patients with rheumatic heart disease (RHD) who were undergoing valve

229 acute rheumatic fever (ARF) and its sequel, rheumatic heart disease (RHD), continue to cause a large

230 he South Pacific experience a high burden of rheumatic heart disease (RHD).

231 hest prevalence rates of clinically detected rheumatic heart disease (RHD).

232 ntially powerful tool for early diagnosis of rheumatic heart disease (RHD).

233 Rheumatic heart disease according to the World Heart Fed

234 Rheumatic heart disease affects 1 in 100 schoolchildren

235 rval, 29.7 million to 43.1 million) cases of rheumatic heart disease and 10.5 million (95% uncertaint

236 re is no vaccine to prevent diseases such as rheumatic heart disease and invasive streptococcal infec

237 ive autoantibodies which target the valve in rheumatic heart disease and the neuronal cell in Sydenha

238 countries, including the cardiac effects of rheumatic heart disease and the vascular effects of mala

239 arly detection and the treatment of clinical rheumatic heart disease are required to improve outcomes

240 ds in the prevalence of and mortality due to rheumatic heart disease as part of the 2015 Global Burde

241 Global age-standardized mortality due to rheumatic heart disease decreased by 47.8% (95% uncertai

242 atically reviewed data on fatal and nonfatal rheumatic heart disease for the period from 1990 through

243 ort the 2-year follow-up of individuals with rheumatic heart disease from 14 low- and middle-income c

244 llion) disability-adjusted life-years due to rheumatic heart disease globally.

245 Although rheumatic heart disease has been nearly eradicated in hi

246 The health-related burden of rheumatic heart disease has declined worldwide, but high

247 Patients with clinical rheumatic heart disease have high mortality and morbidit

248 an monoclonal antibodies (mAbs) derived from rheumatic heart disease have provided evidence for cross

249 interval, 297,300 to 337,300) deaths due to rheumatic heart disease in 2015.

250 mary prevention of acute rheumatic fever and rheumatic heart disease in children presenting with phar

251 e current management strategies for valvular rheumatic heart disease on the basis of either strong ev

252 pared with other primary presentations) were rheumatic heart disease or congestive cardiac failure, c

253 the mortality and morbidity associated with rheumatic heart disease or information on their predicto

254 surface antigens may lead to valve damage in rheumatic heart disease or neuropsychiatric behaviors an

255 l disease prevalence of and mortality due to rheumatic heart disease over a 25-year period.

256 Acute rheumatic fever and rheumatic heart disease remain major global health probl

257 Acute rheumatic fever and subsequent rheumatic heart disease remain significant in developing

258 Rheumatic heart disease remains an important preventable

259 one transitions in developed countries, from rheumatic heart disease to a degenerative calcific patho

260 The prevalence of borderline or definite rheumatic heart disease was 10.2 (95% CI, 7.5-13.0) per

261 ndardized mortality due to and prevalence of rheumatic heart disease were observed in Oceania, South

262 Children with rheumatic heart disease were older than children without

263 se, nonischemic and Chagas cardiomyopathies, rheumatic heart disease, and congenital heart anomalies,

264 ion, aortic and peripheral arterial disease, rheumatic heart disease, and endocarditis.

265 iomyopathy, atrial fibrillation and flutter, rheumatic heart disease, aortic aneurysm, peripheral art

266 ally associated with intravenous drug abuse, rheumatic heart disease, prosthetic heart valves, pacema

267 predominantly communicable diseases such as rheumatic heart disease, tuberculous pericarditis, or ca

268 nd its peptides appear during progression of rheumatic heart disease.

269 ad prosthetic valve endocarditis, and 5% had rheumatic heart disease.

270 including cardiac surgery for congenital and rheumatic heart disease.

271 sorders, including schistosomiasis, HIV, and rheumatic heart disease.

272 T cells in peripheral blood and in rheumatic heart valves revealed the presence of T cells

273 The presence of rheumatic, hepatobiliary, pancreatic, and dermatologic d

274 with diabetes mellitus (DM) and concomitant rheumatic illness to measure changes in HbA(1c) after st

275 coronary disease) in developed countries, or rheumatic (in developing countries).

276 ising new tool for uncovering and monitoring rheumatic inflammation in vivo.

277 cytokines and are abundantly present in the rheumatic joint, induce proinflammatory cytokine express

278 target C3 breakdown products deposited in a rheumatic joint.

279 ecules that trigger complement activation in rheumatic joints.

280 To evaluate the rheumatic manifestations associated with HIV infection i

281 The overall prevalence of rheumatic manifestations in HIV population is approximat

282 le, clinicians should be familiar with these rheumatic manifestations in order to avoid misdiagnosis

283 Very often, the presentation of rheumatic manifestations is the initial presentation of

284 Rheumatic manifestations may often be the initial presen

285 ge, and as molecular techniques advance, the rheumatic manifestations of infectious diseases are incr

286 human atrial tissues from the patients with rheumatic mitral valve disease in either sinus rhythm or

287 ch other to promote the development of AF in rheumatic mitral valve disease.

288 A total of 128 patients with rheumatic MS without other significant valve disease wer

289 ell types valuable for clinical treatment of rheumatic pathologies.

290 combinations of immunosuppressive therapy in rheumatic patients.

291 ysiology, outcome measures, and therapies of rheumatic skin disease.

292 current state of the art for the most common rheumatic skin diseases.

293 osphate dihydrate deposition disease or as a rheumatic symptom such as diffuse arthralgia.

294 on may alter the diagnosis and management of rheumatic symptoms, as well as trigger new research oppo

295 thogenic link between the malignancy and the rheumatic syndrome, the association between these diseas

296 Although paraneoplastic rheumatic syndromes are rare, clinicians should be aware

297 gs are continuously being developed and some rheumatic syndromes have been associated with specific d

298 ected individuals can be affected by various rheumatic syndromes including arthritis, spondyloarthrit

299 PURPOSE OF REVIEW: To describe rheumatic syndromes that can be a paraneoplastic manifes

300 VIEW: Cocaine use is associated with several rheumatic syndromes.

301 lvular surgery, hypertrophic cardiomyopathy, rheumatic valvular disease, or greater than mild mitral